Overactive Bladder Treatment Market to Reach $6.5 Billion by 2035

Overactive bladder treatment market was valued at $3.2 billion in 2025 and is projected to reach $6.5 billion by 2035, growing at a CAGR of 7.3% over the forecast period (2026–2035). The increasing prevalence of urinary disorders, coupled with the rising aging population and advancements in pharmacological and neuromodulation therapies, is driving sustained demand for overactive bladder (OAB) treatment solutions. Therapeutic approaches such as anticholinergics, beta-3 adrenergic agonists, and neurostimulation devices are becoming essential in managing bladder dysfunction, as patients increasingly seek effective and long-term treatment options.

Browse the full report description of “Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, By Therapy (Anticholinergics, Intravesical Instillation, Mirabegron, Neurostimulation, Others), By Application (Neurogenic Overactive Bladder, Idiopathic Overactive Bladder), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centres), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/overactive-bladder-treatment-market

The rapid growth in the global aging population is a key driver for the overactive bladder treatment market. According to the World Health Organization, the global population aged 60 years and above is expected to reach 2.1 billion by 2050, up from 1 billion in 2020. Aging is strongly associated with bladder dysfunction, significantly increasing the prevalence of OAB conditions. As life expectancy increases globally, the burden of chronic conditions such as urinary incontinence and bladder disorders is rising. Older adults are more likely to require continuous pharmacological treatment or advanced therapies such as neuromodulation. This demographic shift is directly contributing to higher diagnosis rates and increased adoption of OAB treatment solutions, supporting long-term market growth.

The increasing prevalence of urinary disorders is further accelerating market expansion. According to OECD data, urinary incontinence and bladder disorders affect approximately 15–20% of adults over the age of 40. This highlights a significant and growing patient population requiring medical intervention. Improved awareness, screening programs, and access to healthcare services are leading to higher diagnosis rates globally. As more patients seek treatment, demand for both pharmacological and minimally invasive therapies is rising. This expanding patient base is expected to drive consistent growth in drug sales, procedural volumes, and device adoption across healthcare settings. Within the therapy landscape, Mirabegron (Beta-3 Adrenergic Agonists) is emerging as the fastest-growing segment. Its improved safety and tolerability profile drives this growth compared to traditional anticholinergic drugs, which are often associated with side effects such as dry mouth and cognitive impairment. Pharmaceutical companies are increasingly focusing on developing and expanding beta-3 agonist therapies to enhance patient compliance and treatment outcomes. The segment is benefiting from strong clinical adoption, particularly among elderly patients, and is expected to capture a growing share of total market revenue over the forecast period.

Recent Developments and Strategies

• In April 2025, Eisai Co., Ltd. and KYORIN Pharmaceutical Co., Ltd. launched Beova tablets in Thailand for overactive bladder treatment. Beova is a once-daily ?3-adrenergic receptor agonist that helps relax the bladder and reduce urgency, frequent urination, nocturia, and urge urinary incontinence.

• In December 2024, Sumitomo Pharma America (manufacturer) announced US FDA approval of GEMTESA (vibegron) for men with overactive bladder receiving pharmacological therapy for benign prostatic hyperplasia (BPH), expanding its indication. Official Press Release. this expands the addressable OAB patient population by including a large comorbid segment (OAB + BPH) and strengthens the ?3 agonist class, as the therapy is now approved for both general OAB and BPH-associated cases, driving higher adoption and prescription growth.

 
Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o By Therapy
  o By Application
  o By End User

Competitive Landscape Astellas Pharma Inc., AbbVie Inc., Pfizer Inc., Medtronic plc, Axonics, Inc., among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Overactive Bladder Treatment Market Report Segment

By Therapy

• Anticholinergics
• Intravesical Instillation
• Mirabegron
• Neurostimulation
• Others

By Application

• Neurogenic Overactive Bladder
• Idiopathic Overactive Bladder

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)

Global Overactive Bladder Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/overactive-bladder-treatment-market